242 related articles for article (PubMed ID: 22194608)
1. FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2).
Zhao Z; Choi J; Zhao C; Ma ZA
J Biol Chem; 2012 Feb; 287(8):5562-73. PubMed ID: 22194608
[TBL] [Abstract][Full Text] [Related]
2. FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice.
Moon H; Chon J; Joo J; Kim D; In J; Lee H; Park J; Choi J
Diabetes Metab Res Rev; 2013 Jan; 29(1):19-24. PubMed ID: 22936676
[TBL] [Abstract][Full Text] [Related]
3. Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.
Jörns A; Akin M; Arndt T; Terbish T; Zu Vilsendorf AM; Wedekind D; Hedrich HJ; Lenzen S
J Mol Med (Berl); 2014 Jul; 92(7):743-55. PubMed ID: 24599515
[TBL] [Abstract][Full Text] [Related]
4. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.
Hofmann U; Hu K; Walter F; Burkard N; Ertl G; Bauersachs J; Ritter O; Frantz S; Bonz A
Br J Pharmacol; 2010 Jul; 160(5):1243-51. PubMed ID: 20590616
[TBL] [Abstract][Full Text] [Related]
6. Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720.
Truong W; Emamaullee JA; Merani S; Anderson CC; James Shapiro AM
Am J Transplant; 2007 Aug; 7(8):2031-8. PubMed ID: 17617868
[TBL] [Abstract][Full Text] [Related]
7. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Schaper K; Dickhaut J; Japtok L; Kietzmann M; Mischke R; Kleuser B; Bäumer W
J Dermatol Sci; 2013 Jul; 71(1):29-36. PubMed ID: 23643308
[TBL] [Abstract][Full Text] [Related]
9. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.
Zhao R; Yang HY; Shin J; Phan L; Fang L; Che TF; Su CH; Yeung SC; Lee MH
Cell Cycle; 2013 Mar; 12(6):935-43. PubMed ID: 23421998
[TBL] [Abstract][Full Text] [Related]
10. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
11. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
12. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.
Keller CD; Rivera Gil P; Tölle M; van der Giet M; Chun J; Radeke HH; Schäfer-Korting M; Kleuser B
Am J Pathol; 2007 Jan; 170(1):281-92. PubMed ID: 17200201
[TBL] [Abstract][Full Text] [Related]
14. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
15. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Gasperini C; Ruggieri S
Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
[TBL] [Abstract][Full Text] [Related]
16. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
18. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
20. Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model.
Moon MH; Jeong JK; Lee JH; Park YG; Lee YJ; Seol JW; Park SY
Exp Mol Med; 2012 Oct; 44(10):603-14. PubMed ID: 22859500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
